Highlights UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
13.27 ^USD	-1.34%		-7.85%	-11.53%

05-07	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	MT
05-05	UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	05-07	MT
UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	05-05	CI
UroGen Pharma Ltd. Reports New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer	05-04	CI
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	04-15	MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	04-03	MT
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102	01-24	CI
Urogen Pharma Ltd. Enters into A License and Supply Agreement (The Agreement) with Medac Gesellschaft Für Klinische Spezialpräparate m.b.H	01-17	CI
UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024	01-17	CI
UroGen Signs Licensing Deal With Medac to Develop New Formulation for Urothelial Cancer; Shares Rise	01-17	MT
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Earnings Flash (URGN) UROGEN PHARMA Reports Q3 Revenue $20.9M, vs. Street Est of $20M	11-14	MT
UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023	11-14	CI
UroGen Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Earnings Flash (URGN) UROGEN PHARMA Posts Q2 Revenue $21.1M, vs. Street Est of $20.1M	10/08/23	MT
UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023	10/08/23	CI
UroGen Stock Up 49% on Full Enrollment for Bladder Cancer Study	27/07/23	DJ
UroGen Pharma Ltd. Announces Positive Topline Data From its Phase 3 Trials ATLAS and ENVISION studying UGN-102	27/07/23	CI
UroGen Pharma Ltd. Announces Retrospective Study Finds Jelmyto Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors That Impede Kidney Preservation	10/07/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Highlights

Filters